Aro Biotherapeutics

Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases

Drug discovery,drug development,licensing,drug delivery,sirna,immunology,bispecifics,protein conjugation,protein therapeutics,oligonucleotide delivery,protein engineering,targeted nanoparticles,genetic medicine,tissue-specific targeting,and biotechnology

Aro biotherapeutics operates in the Biotechnology industry.

Aro biotherapeutics's revenue is 1m - 10m

Aro biotherapeutics has 11 - 50 employees.